ABSTRACT Background: Despite evidence of antioxidant effects of vitamin E in vitro and in animal studies, large, randomized clinical trials have not substantiated a benefit of vitamin E in reducing inflammation in humans. An individual's genetic background may affect the response to a-tocopherol supplementation, but this has rarely been investigated. Objective: The aim of this study was to explore the role of genetic polymorphisms on changes in LPS-stimulated inflammatory cytokine production from peripheral blood mononuclear cells (PBMCs) after a-tocopherol supplementation. Design: A total of 160 healthy, middle-aged male volunteers (mean age: 52.7 y) were given dietary supplements of either 75 IU (low dose; n = 57) or 600 IU (high dose; n = 103) a-tocopherol/d for 6 wk. The production of TNF-a and IL-1b, -6, and -10 by PBMCs after LPS stimulation was measured at baseline and after 6 wk. Polymorphisms in 15 genes involved in inflammation or responses to oxidative stress were characterized in the subjects. Results: The ability of a-tocopherol to affect TNF-a production by LPS-stimulated PBMCs was influenced by the TNFA 2238 polymorphism (P = 0.016). The ability of a-tocopherol to affect IL-6 production was influenced by the GSTP1 313 polymorphism (P = 0.019). The ability of a-tocopherol to affect IL-1b production was influenced by the IL10 2592 and 21082 polymorphisms (P = 0.025 and P = 0.016, respectively). Conclusions: In healthy control subjects, the effect of a-tocopherol supplementation on the production of inflammatory cytokines appears to be dependent on an individual's genotype. These genotype-specific differences may help explain some of the discordant results in studies that used vitamin E.
INTRODUCTION
Vitamin E, especially a-tocopherol, exhibits antioxidant and antiinflammatory activities and inhibits several events involved in the initiation and progression of atherogenesis (1) (2) (3) (4) (5) . Despite promising findings from cell culture and animal models, the results of cohort and supplementation studies with a-tocopherol in humans have been equivocal and controversial. Data from the Nurses' Health Study, which is a prospective cohort of .80,000 US nurses, showed a 30% reduction in risk of developing coronary artery disease in subjects who took vitamin E supplements after adjustment for age, smoking status, and intakes of carotene and vitamin C (6) . However, a cohort study of 5133 Finnish residents who were followed for 14 y showed no reduction in coronary artery disease mortality with vitamin E supplementation (7) . The Physicians' Health Study, which was conducted in .80,000 male US physicians, also showed no association between vitamin E supplement use and cardiovascular mortality (8) . Interventional trials that investigated the effect of a-tocopherol supplementation on cardiovascular and inflammatory endpoints have also yielded mixed results (9, 10) . These studies showed that a-tocopherol either was not beneficial or was beneficial for certain outcomes (such as nonfatal myocardial infarction) but not others (fatal coronary artery disease) or was beneficial only for certain types of patients (eg, patients with compromised antioxidant activity) or, at high doses, was harmful (9, 10) . Thus far, these inconsistent observations have not been well explained. Explanations offered by the authors of the studies included the inadequate selection of subjects (by, eg, sex or vitamin E status) or of the dose, timing of intake, and chemical form of vitamin E. One aspect that has been infrequently addressed is the influence that an individual's genetic background may have on the response to a-tocopherol supplementation. In this regard, Belisle et al (11) showed that the effect of vitamin E on a respiratory tract infection was partly dependent on polymorphisms in the promoter region of the gene that encodes the cytokine IL-10. Although the study investigated the influence of several cytokine gene polymorphisms on the clinical outcome in relation to vitamin E supplementation, it did not report on cytokine production. In the current study, the genotype-a-tocopherol interaction was investigated with respect to the effect on inflammatory cytokine production. Inflammatory cytokines were selected for study because the balance between proinflammatory and antiinflammatory cytokines, such as IL-1, -6, and -10 and TNF-a plays an important part in atherosclerotic plaque development and stability (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . We selected 21 variants in 15 genes known to influence an individual's inflammatory response or response to oxidative stress (ie, the presence of reactive oxygen species with the potential to cause damage to the host) and assessed the role that polymorphisms in these genes have on the ability of peripheral blood mononuclear cells (PBMCs) to produce inflammatory cytokines after stimulation with bacterial LPS, as a biomarker of the inflammatory capacity, in healthy men before and after 6 wk of a-tocopherol supplementation.
SUBJECTS AND METHODS

Subjects and study design
All procedures that involved human participants were approved by the Southampton and South West Hampshire Research Ethics Committee (ethical submission no. 413/02/T). Subjects were recruited by using advertising strategies that included posters, e-mail, and local media advertisements. Healthy men (aged 35-70 y) were invited to participate in the study. Volunteers were excluded if they took glucocorticoids (including prednisolone, hydrocortisone, or dexamethasone). Subjects were also asked to avoid the use of nonsteroidal antiinflammatory drugs during the study. Eligibility to enter the study was assessed by using a screening questionnaire. Written informed consent was given by all participants who entered the study. Most participants were white, and no participant had taken any dietary supplements within 12 wk of entering the study. Healthy, middle-aged, male volunteers (mean age: 53 6 10 y) were given dietary supplements of either 75 IU (low dose; n = 57) or 600 IU (high dose; n = 103) a-tocopherol (RRR-a-tocopherol)/d for 6 wk; a-tocopherol was provided by Lamberts Healthcare and, in both cases, was in the form of a single tablet. Characteristics of the subjects assigned to each group are given in Table 1 . The high-dose group was initiated in April 2003; when a meta-analysis was published that suggested possible harmful effects of high-dose vitamin E (10), no further assignments to the high-dose group were made and the study was halted while ethical advice was sought. Later, in April 2005, the low-dose group was initiated. All subjects completed the study by December 2005. Study participants continued with their normal diets and normal daily activities while receiving the supplements. At study entry and after 6 wk of supplementation, subjects attended the Wellcome Trust Clinical Research Facility at Southampton University Hospital Trust after an overnight fast. At each visit, weights, heights, and waist and hip circumferences were measured, and blood samples were collected into heparin and EDTA.
Biochemical analyses
Plasma and PBMCs were prepared from heparinized blood. The concentration of a-tocopherol in plasma was determined by using fluorimetry according to methods described elsewhere (22) . The limit of detection of a-tocopherol was 7.2 pmol/L. PBMCs were isolated from heparinized whole blood by using Leucosep sterile centrifuge tubes (Greiner Bio-one) and histopaque gradient solution (Sigma-Aldrich Inc).
PBMC culture and cytokine determination
PBMCs (2 · 10 6 per well) were cultured in Roswell Park Memorial Institute 1640 (Sigma-Aldrich Inc) in the presence of LPS (final concentration: 10 lg/mL on the basis of preliminary studies that showed this dose to elicit high cytokine concentrations in the medium after 24 h) (Sigma-Aldrich Inc) in a 95% air and 5% CO 2 atmosphere at 37°C for 24 h, after which time the supernatant fluid was removed and stored at 280°C until analysis. Concentrations of TNF-a and IL-1b, -6, and -10 in cell culture supernatant fluid were determined by using a cytometric bead array human inflammation kit (BD Bioscience) and flow cytometry for detection. All operations were performed according to the manufacturer's instructions. The intensity of the fluorescence signal was acquired by using a FACSCalibur flow cytometer (Becton Dickinson) and analyzed with CBA software. The concentration range for detection with the use of this assay is 20-5000 pg/mL for each cytokine.
Genotyping DNA was extracted from EDTA anticoagulated blood by using a salting-out method as previously described (23) . Briefly, cell membranes were lysed by using detergent, and proteins were digested by using proteinase K (Sigma-Aldrich Inc) and removed in 6 mol/L sodium chloride (Sigma-Aldrich Inc) with centrifugation. DNA was precipitated from the remaining solution in ethanol, dried, and dissolved in distilled water. Genotyping was performed by using the Taqman ABI 7700 sequence-detection system (Applied Biosystems). The variants examined in the genes TNFA, LTA, IL10, SLC11A1, IL6, NOS3, IL1A, IL1B, IL4, PPARG, MTHFR, SOD2, GSTM1, GSTT1, and GSTP1 are listed in Table 2 . With the exception of the null GSTM1 and GSTT1 variants for which only 2 genotype states are possible (present or null), all genotypes were in Hardy-Weinberg equilibrium (Table 2) .
Statistical methods
Apart from genetic association analyses, SPSS 17.0 software (SPSS Inc) was used for data analysis. Comparisons between or within groups were made by using ANOVA (factors: time, a-tocopherol, and dose), and pairwise comparisons were made by using Student's t test. Comparisons of cytokine production at study entry according to genotype were made by using ANOVA (factor: genotype). Corrections were made for multiple testing, and P , 0.05 was taken to indicate a statistically significant difference. S-Plus 6.0 software (Insightful Corp) was used for genetic-association analysis. A co-dominant (additive) genetic model was tested, which assumed that the mean value of a trait (in this case, the change in cytokine production by PBMCs) for the heterozygote was between that of the homozygotes. Thus, the genotype was coded as follows: 0 = a major allele homozygote, 1 = a heterozygote, and 2 = a minor allele homozygote. A linear regression was carried out in which the outcome variable was
where DCk is the change in the cytokine concentration from baseline (Ck refers to TNF-a or IL-1, -6, or -10), and minDCk is the most negative DCk (,0) observed in the population; the 1 All values are P values for the association across genotypes for the listed polymorphisms and LPS-stimulated cytokine production at baseline after correction for age, BMI, and smoking status (1-factor ANOVA; factor: genotype). P , 0.05 was taken to indicate statistical significance. PBMCs, peripheral blood mononuclear cells. baseline value, a-tocopherol-dose group, smoking status, age, and BMI were included as covariates. The false discovery rate probability method (24) was used to adjust for multiple testings.
RESULTS
Baseline characteristics and a-tocopherol concentrations
There were no significant differences in age, smoking status, or BMI between the 2 treatment groups (Table 1) . Subjects in the highdose a-tocopherol group tended to have higher a-tocopherol concentrations at baseline (P = 0.065). Supplementation with a-tocopherol increased plasma a-tocopherol concentrations (P , 0.001 in both low-and high-dose groups) with a greater increase in the high-dose group (with an average 71% increase in the high-dose group and an average 37% increase in the low-dose group) ( Table 1) .
Effect of genotypes on cytokine production
There was a limited effect of genotypes assessed on the baseline production of TNF-a and IL-6 and -10 ( Table 3) ; 2 genotypes that encoded IL-10 (IL10 2819 and IL10 2592) affected baseline IL-10 production. All genotypes assessed were associated with baseline IL-1b production ( Table 3) .
Effect of a-tocopherol on cytokine production
The cytokine production by LPS-stimulated PBMCs in the 2 treatment groups before and after a-tocopherol supplementation is shown in Table 4 . There were no differences in the production of TNF-a or IL-1b or -6 between groups at baseline or after a-tocopherol supplementation (Table 1) . However, there was an effect of time on the production of these 3 cytokines (P = 0.003, P = 0.007, and P , 0.001, respectively; 2-factor ANOVA), such that the production was higher after supplementation than before with no significant effect of dose. The production of IL-10 was lower in the low-dose a-tocopherol group but was not affected by a-tocopherol supplementation (Table 4) .
Change in cytokine production with a-tocopherol according to genotype
The change in LPS-stimulated cytokine production after 6 wk of a-tocopherol supplementation (low-and high-dose groups combined) was compared between genotypes with adjustment for baseline cytokine production, age, BMI, smoking status, and a-tocopherol dose. Before adjustment for multiple testing, several polymorphisms were shown to be associated with the change in cytokine production ( Table 5) . After correction for multiple testing, the effect of a-tocopherol on TNF-a production was different (P = 0.016) between GG and GA genotypes for TNFA 2238 ( Figure 1A) . After correction for multiple testing, the effect of a-tocopherol on IL-6 production was different (P = 0.019) according to the genotype for GSTP1 313 as follows ( Figure 1B ): the change in IL-6 production was different in individuals with the GG genotype than in subjects with the AA or AG genotype. After correction for multiple testing, 2 of the polymorphisms examined had an effect on the response to a-tocopherol of IL-1b production (Table 4) . These were the IL10 2592 and at IL10 21082 polymorphisms. The minor genotype for IL10 2592 (AA) showed the larger increase in IL-1b production in response to a-tocopherol ( Figure 1C) , whereas the IL10 21082 AA genotype also showed the larger increase in IL-1b production in response to a-tocopherol ( Figure 1D ). Changes in IL-1b production in subjects with IL10 2592 CC and IL10 21082 GG genotypes were not different from zero. After correction for multiple testing, none of the polymorphisms examined had an effect on the response to a-tocopherol of IL-10 production (Table 5 ).
DISCUSSION
In this study, we showed that, in healthy men, the ability of a-tocopherol supplementation to change the PBMC production of cytokines after LPS-stimulation was dependent on genotype. To our knowledge, this was the first time that this genotype-a-tocopherolinflammation interaction has been described, although such interactions have been observed for the influence of fatty acids on inflammatory outcomes (25, 26) . Oxidative stress, induced under a variety of conditions and acting via nuclear transcription factor FIGURE 1. Mean (6SEM) changes in LPS-stimulated cytokine production by peripheral blood mononuclear cells after 6 wk of aT supplementation according to genotype. A: Change in TNF-a production according to TNF 2238 genotype (GG and GA genotypes different, P = 0.016; general linear regression model corrected for multiple comparisons by using the FDR probability method). B: Change in IL-6 production according to GSTP1 313 genotype (genotypes different, P = 0.019; general linear regression model corrected for multiple comparisons by using the FDR probability method). C: Change in IL1b according to genotype for the IL10-592 (genotypes different, P = 0.025; general linear regression model corrected for multiple comparisons by using the FDR probability method). D: Change in IL-1b according to genotype for the IL10-1082 (genotypes different, P = 0.016; general linear regression model corrected for multiple comparisons by using the FDR probability method). Values are from the indicated number of subjects. aT, a-tocopherol; FDR, false discovery rate.
jB, is known to lead to the enhanced liberation of proinflammatory chemokines and cytokines (27) . Thus, a decrease in oxidative stress should be conducive to a decreased release of proinflammatory cytokines. However, this effect was not seen in the current study; instead, a-tocopherol increased inflammatory cytokine production irrespective of the dose used (Table 4) , and this effect was dependent on the genotype, with some genotypes that showed decreased inflammatory responses (Table 5 ; Figure 1 ). This result suggests that genotype is an important determinant of the effect of a-tocopherol on inflammatory outcomes.
The results from large clinical trials with a-tocopherol on risk of cardiovascular disease, which is strongly influenced by inflammation, have been mostly negative (28) (29) (30) . Other studies in subjects with enhanced oxidative stress associated with endstage renal disease (31), subjects with elevated blood cholesterol concentration (32) , and, in combination with vitamin C, subjects who were undergoing an organ transplantation (33) , have been more promising and showed a benefit from a-tocopherol. A study in subjects with type 2 diabetes (34) showed that plasma markers of oxidative stress decreased as a result of a-tocopherol and c-tocopherol supplementation, but plasma markers of inflammation such as C-reactive protein, monocyte chemoattractant protein-1, TNF-a,and IL-6 showed no improvement.
Belisle et al (11) reported that supplementation with 200 IU all-rac-a-tocopherol for 1 y in elderly nursing home residents influenced respiratory tract infections differently according to the cytokine genotype. Belisle et al (11) showed that the IL10 2819 polymorphism affected whether a-tocopherol decreased risk of total and lower respiratory tract infections in women. The effect of this polymorphism on infections in women may relate to an altered inflammatory response that is, in turn, sensitive to the effect of a-tocopherol. This effect did not occur in men, which suggested a sex-genotype-vitamin E interaction. In the current study, we did not see an effect of the IL10 2819 polymorphism on the change in cytokine production or effect of a-tocopherol in men. Belisle et al (11) reported that a number of other cytokine gene polymorphisms had no effect on either risk of respiratory infection or impact of a-tocopherol. We also studied several of these polymorphisms. We showed no effect of TNF 2308, IL6 2174 or the IL1B 2511 polymorphisms on the response of inflammatory cytokine production to increased a-tocopherol in men. The subtle sex-genotype-vitamin E interactions uncovered may go some way to explain differences observed for the impact of the use of vitamin E supplements in large epidemiologic studies of women and men (6, 8) .
The GG genotype at GSTP1 313 has been implicated in a decreased response to oxidative stress [eg, the response to ozone exposure (35) or smoking (36) ], which suggested that this genotype is associated with a poorer antioxidant capacity (ie, an impaired ability to deal with oxidative stress). In the current study, this genotype was associated with lower IL-6 production after a-tocopherol supplementation. This association suggested that the individuals who will benefit the most from a-tocopherol treatment (because of the reduced inflammatory potential of PBMCs) are those who have a lower baseline antioxidant capacity. It is possible that subjects with a lower antioxidant capacity because of their genetic background will derive a greater advantage from a-tocopherol supplementation. This advantage would appear consistent with what has been observed in clinical trials, in which individuals with an impaired antioxidant capacity have been reported to draw the greatest health benefit in terms of decreased risk of cardiovascular disease from vitamin E (12) .
Limitations of this study are that there was no record of dietary intake, a placebo (control) group was not included, different numbers of subjects were assigned to the 2 a-tocopherol doses, we did not assess oxidative stress or antioxidant capacity (apart from the plasma a-tocopherol concentration), only men were studied, and the mechanism that underlies the a-tocopherol-genotype interaction was not investigated. However, baseline fasting plasma concentrations of a-tocopherol were recorded, and there was no significant difference between low-and high-dose groups (P = 0.065).
In conclusion, these results indicate that the effect of a-tocopherol supplementation on the inflammatory response is a function of an individual's genotype. The data suggest that individuals with a lower antioxidant capacity might be those who would benefit the most from intake of a-tocopherol.
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